We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Supercomputers Used to Create Synthetic, Germ-Fighting Compounds

By LabMedica International staff writers
Posted on 16 Apr 2009
Since studies indicate that bacteria have little or no ability to resist antimicrobial peptides, one of the most fascinating possibilities of this finding is the creation of new forms of antibiotics to fight bacteria that have become resistant or immune to conventional drugs. More...
Scientists are now utilizing supercomputers to design and create synthetic small organic molecules and polymers--easier to make than peptides--that have the same mechanism of action as host defense proteins and with similar germ-fighting ability.

Based on the success of this research, scientists from the University of Pennsylvania (Philadelphia, PA, USA) filed for several patents and spun off of a biotech company named PolyMedix, Inc. (Radnor, PA, USA) to investigate the possibilities for useful applications as both novel therapeutic antibiotic drugs and as antimicrobial polymers for biomaterials applications.

These investigational antibiotic agents are the first of their kind to directly address the serious medical problem of bacterial drug resistance. The host defense proteins work essentially differently from all other known antibiotics: they punch holes directly in bacterial cell membranes, via a biophysical instead of a biochemical mechanism of action, in ways that makes resistance unlikely to develop. Up to now, data from a phase I study demonstrate that the compound is safe, and well-tolerated single doses were achieved at levels suggesting a beneficial therapeutic index. Additional clinical development will continue for the initial indication for this drug as a treatment for pan-Staphylococcal infections.

Staphylococcus aureus colonizes, without infecting, up to 30% of the human population. With the superbug's ubiquity and ability to invade almost any environment, no place is considered a safe haven against this deadly bacteria. Drug-resistant bacterial infections are one of the most significant medical problems facing the global population. Once typically thought of as a cure-all, antibiotics were the initial line of defense. Unfortunately, bacteria are becoming resistant to antibiotics due to overuse. While antibiotics-resistant superbugs are indeed a terrifying medical development, these newer innovative therapies suggest they are not invulnerable.

Related Links:

University of Pennsylvania
PolyMedix



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.